Taken together, this study contributes to the clinical management of IEI by providing a rationale for essential specific treatment options, such as TNF inhibitors for ADA2 deficiency (42), abatacept for LRBA deficiency (43), and HSCT for XIAP deficiency. Here, ADA2 is linked to hyperinsulinemic hypoglycemia, familial, 4.